RBD Dimer recombinant protein vaccine against SARSCoV2

Información del proyecto

RBDCOV

Identificador del acuerdo de subvención: 101046118

DOI

10.3030/101046118

Proyecto cerrado

Fecha de la firma de la CE 12 Noviembre 2021

Fecha de inicio 1 Diciembre 2021

Fecha de finalización 31 Agosto 2025

Financiado con arreglo a

• Health

Coste total

€ 9 779 211,26

Aportación de la UE

€ 9 779 211,25

Coordinado por

HIPRA SCIENTIFIC SL
Spain

Periodic Reporting for period 2 - RBDCOV (RBD Dimer recombinant protein vaccine against SARSCoV2)

Período documentado: 2023-03-01 hasta 2024-05-31

Resumen del contexto y de los objetivos generales del proyecto

RBDCOV aims to test the efficacy, tolerability, and safety of the HIPRA vaccine for COVID-19. HIPRA's vaccine is an adjuvanted recombinant protein vaccine, based on a receptor binding domain (RBD) fusion heterodimer against SARS-CoV-2. RBDCOV aims to generate robust data to demonstrate the safety and immunogenicity of this vaccine given as a booster vaccination to induce a higher and more durable immune response, for potential new variants. It should be effective in the prevention of COVID-19.

The initiative is an innovative vaccine-focused research project that brings together the expertise of a number of European organisations and companies.To achieve the project objectives, it is crucial involve as many European stakeholders as possible. That is why the RBDCOV consortium rely on the expertise and the experience of the 12 project partners. The RBDCOV benefits from the perspective of specific populations, i.e. People with immunocompromising conditions, that have been largely excluded from Phase III trials with already authorised SARS-CoV2 vaccines, as vaccine-related immune responsiveness is unclear in this population, who are at higher risk of severe COVID-19.

https://rbdcov.eu/

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

During the second reporting period (RP2), the RBDCOV project made substantial progress in testing the efficacy, safety, and tolerability of the HIPRA-developed COVID-19 vaccine (BIMERVAX®) in vulnerable groups. Key milestones included paediatric trials with 350 children and trials for 240 immunosuppressed adults. Manufacturing capabilities were enhanced, and new formulations were developed for emerging variants. Significant regulatory and public engagement efforts were made, positioning the vaccine for broad use and commercialization.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

An ideal COVID-19 vaccine should have high protective efficacy and be safe and deployable for billions of potential vaccinees. To achieve this goal, an optimal vaccine target, platform and dose regimen are important . Therefore, development of a range of COVID-19 vaccines with different mechanisms of action would be beneficial to diversify the global vaccine pipeline.

RBDCOV is an ambitious project that will offer a new tool to control the pandemic at short-medium and long term. RBDCOV aims to manufacture and test the first recombinant protein-based vaccine to be authorised in Europe beyond the framework of the project. The final formulation of RBDCOV vaccine based on the results on safety and efficacy (obtained during the assessment of different formulations, the experience of the company in using highly innovative platforms for vaccine manufacturing in animals and the solid consortium included in the RBDCOV project will make feasible to settle the bases for this challenging objective.

rbdcov-vaccine29sep-2048x1236.png